Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. reports developments tied to its commercial eye-care franchise and biopharmaceutical pipeline. Company news commonly covers XDEMVY, its lotilaner ophthalmic solution marketed in the U.S. for Demodex blepharitis, including product-sales updates, prescribing trends, conference presentations, and international regulatory milestones for TP-03 through its Greater China partner.
Updates also address pipeline programs such as TP-04 for ocular rosacea and TP-05, an investigational oral lotilaner tablet being studied for Lyme disease prevention. Recurring corporate items include quarterly and annual financial results, investor-conference participation, board and governance changes, and business updates related to Tarsus' ophthalmology-focused commercialization strategy.
Tarsus (NASDAQ:TARS) reported second quarter 2026 net product sales of $173.9 million for XDEMVY, up more than 69% year-over-year, and raised full-year 2026 XDEMVY net product sales guidance to $685–$705 million. Gross margin remained high at 93%.
The company reported a Q2 2026 net loss of $18.6 million (basic and diluted loss per share $(0.43)), slightly improved from $20.3 million a year earlier. R&D expenses rose to $31.0 million and SG&A to $150.7 million, reflecting expanded clinical programs and commercial investment. Cash, cash equivalents and marketable securities totaled $449.7 million as of June 30, 2026.
Tarsus completed the acquisition of iRenix Medical (IRX-101) and agreed to acquire Alkeus Pharmaceuticals and ALK-001, adding late-stage retina assets. It also priced a $125 million private placement financing and continues multiple Phase 2 and planned Phase 3 programs across ocular rosacea, Lyme disease prophylaxis and ocular antiseptics.
Tarsus Pharmaceuticals (Nasdaq:TARS) entered into a securities purchase agreement for an oversubscribed private investment in public equity (PIPE) expected to generate approximately $125.0 million in gross proceeds, before fees and expenses. The financing includes existing Alkeus Pharmaceuticals investors such as TCGX, Bain Capital Life Sciences, and Wellington Management, alongside new and existing Tarsus investors including ADAR1 Capital Management, Sirenia Capital Management, RTW Investments, and Vestal Point Capital.
Tarsus will sell 2,098,519 shares of common stock at $56.00 per share and pre-funded warrants to purchase 133,625 shares at $55.9999 per warrant, with an exercise price of $0.0001 per share. Closing is expected on August 7, 2026, subject to customary conditions. According to Tarsus, net proceeds will fund clinical development, commercial activities, and general corporate purposes. Barclays acts as lead placement agent, with BofA Securities and William Blair as co-placement agents.
Tarsus Pharmaceuticals (Nasdaq:TARS) entered a definitive agreement to acquire retinal disease-focused Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a once-daily oral Phase 3 candidate for Stargardt disease, a large inherited retinal disease with no FDA-approved therapy. The transaction includes approximately $450 million upfront (about $270 million in cash and $180 million in Tarsus common stock), plus up to $350 million in potential regulatory and first-commercial-sale milestones and low single-digit tiered descending royalties on net sales.
ALK-001 has been studied in 400+ individuals, with over seven years of long-term tolerability data and Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations. According to Tarsus, prior studies showed 29.5% slower annual growth of atrophic lesions and an 87% lower likelihood of significant low-light visual acuity loss versus control, informing the ongoing Phase 3 NORTHSTAR trial, which targets ~230 patients and topline data in the second half of 2029. The deal has been approved by both companies’ boards and Alkeus stockholders, and is expected to close in 2026, subject to HSR and other customary conditions, with no financing contingency.
Tarsus (NASDAQ:TARS) announced it will host a live webcast on Thursday, August 6, 2026, at 5:00 a.m. PT / 8:00 a.m. ET to report its second quarter 2026 financial results and provide a corporate update. A recorded version will be available on the company’s website for about 90 days after the webcast.
Tarsus Pharmaceuticals (Nasdaq:TARS) announced an executive leadership transition as Chief Commercial Officer Aziz Mottiwala departs to become CEO of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, is appointed Interim Chief Commercial Officer while a search for a permanent successor is conducted.
According to Tarsus Pharmaceuticals, Clase has been central to the company’s shift from clinical-stage to commercial biopharmaceutical status, contributing to the launch of XDEMVY and long-term growth strategy. The transition follows the commercialization of XDEMVY and the acquisition of iRenix Medical, which expands Tarsus’ eye care pipeline.
Tarsus (NASDAQ:TARS) agreed to acquire iRenix Medical and its late-stage ocular antiseptic IRX-101, aiming to strengthen its eye care portfolio. IRX-101 showed significant pain and corneal damage reduction versus povidone-iodine in a 154-patient Phase 2b/3 trial. Upfront consideration totals about $75 million, with up to $490 million in potential milestones.
A Phase 3 trial is expected to start enrollment in the first half of 2027, with results anticipated in 2028.
Tarsus (NASDAQ:TARS) announced that management will participate in two upcoming investor conferences: the William Blair 46th Annual Growth Stock Conference/b] on June 2 at 8:00 a.m. PT / 11:00 a.m. ET and the on June 3 at 8:40 a.m. PT / 11:40 a.m. ET.
Live webcasts, details, and limited-time replays will be available in the events section of the Tarsus website.
Tarsus (NASDAQ:TARS) announced a partnership with John Cena to raise awareness of Demodex blepharitis, a common eyelid disease affecting about 25 million Americans. The campaign highlights symptoms such as redness, itching and crusting, and promotes regular eye exams and treatment options.
Cena shares his experience being diagnosed with Demodex blepharitis and treated with XDEMVY (lotilaner ophthalmic solution) 0.25%, described as the first and only FDA-approved treatment that directly targets and kills the mites causing the disease.
Tarsus (NASDAQ: TARS) announced management will participate in three investor conferences in May 2026: Bank of America Health Care Conference on May 12 (3:40 p.m. PT / 6:40 p.m. ET), H.C. Wainwright BioConnect on May 19 (8:00 a.m. PT / 11:00 a.m. ET), and Stifel Virtual Ophthalmology Forum on May 26 (12:30 p.m. PT / 3:30 p.m. ET).
Live webcasts and additional details are available on the company's events page. Replays will be posted within 48 hours and archived for a limited time.
Tarsus (NASDAQ: TARS) reported Q1 2026 XDEMVY net product sales of $145.4M, up >85% year-over-year, and reaffirmed full-year 2026 XDEMVY guidance of $670–700M with peak sales potential exceeding $2 billion. Cash and marketable securities totaled $388.7M. The company initiated a Phase 2 trial for TP-05 and expects multiple topline readouts in H1 2027.
Management will host a conference call on May 6, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.